Zimmer Biomet Holdings Free Cash Flow (FCF) History (ZBH)
Zimmer Biomet Holdings reported $1.47B in free cash flow for fiscal 2025, an increase of 13.66% from the previous fiscal year, with a free cash flow margin of 17.89%.
View full Zimmer Biomet Holdings company overviewZimmer Biomet Holdings free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.47B | $177.0M | +13.66% | +17.89% |
| 2024 | 2024-12-31 | $1.30B | $5.1M | +0.40% | +16.87% |
| 2023 | 2023-12-31 | $1.29B | $122.2M | +10.46% | +17.45% |
| 2022 | 2022-12-31 | $1.17B | −$187.3M | −13.82% | +16.83% |
| 2021 | 2021-12-31 | $1.36B | $263.0M | +24.07% | +19.86% |
| 2020 | 2020-12-31 | $1.09B | −$286.1M | −20.75% | +17.83% |
| 2019 | 2019-12-31 | $1.38B | −$206.0M | −13.00% | +17.27% |
| 2018 | 2018-12-31 | $1.58B | $158.4M | +11.11% | +19.98% |
| 2017 | 2017-12-31 | $1.43B | −$21.2M | −1.46% | +18.28% |
| 2016 | 2016-12-31 | $1.45B | $765.4M | +112.21% | +18.88% |
| 2015 | 2015-12-31 | $682.1M | −$233.5M | −25.50% | — |
| 2014 | 2014-12-31 | $915.6M | $52.5M | +6.08% | — |
| 2013 | 2013-12-31 | $863.1M | −$174.1M | −16.79% | — |
| 2012 | 2012-12-31 | $1.04B | −$25.9M | −2.44% | — |
| 2011 | 2011-12-31 | $1.06B | −$51.2M | −4.59% | — |
| 2010 | 2010-12-31 | $1.11B | $101.9M | +10.07% | +26.40% |
| 2009 | 2009-12-31 | $1.01B | $224.3M | +28.46% | +24.72% |
| 2008 | 2008-12-31 | $788.1M | −$103.6M | −11.62% | +19.12% |
| 2007 | 2007-12-31 | $891.7M | — | — | +22.88% |
Zimmer Biomet Holdings quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $393.6M | $65.5M | +19.96% | +18.08% |
| Q1 2026 | 2026-03-31 | $323.1M | −$15.1M | −4.46% | +15.48% |
| Q4 2025 | 2025-12-31 | $442.6M | −$12.2M | −2.68% | +19.73% |
| Q3 2025 | 2025-09-30 | $363.7M | $12.5M | +3.56% | +18.17% |
| Q2 2025 | 2025-06-30 | $328.1M | $11.4M | +3.60% | +15.79% |
| Q1 2025 | 2025-03-31 | $338.2M | $165.3M | +95.60% | +17.72% |
| Q4 2024 | 2024-12-31 | $454.8M | −$70.8M | −13.47% | +22.48% |
| Q3 2024 | 2024-09-30 | $351.2M | $97.9M | +38.65% | +19.25% |
| Q2 2024 | 2024-06-30 | $316.7M | $66.1M | +26.38% | +16.31% |
| Q1 2024 | 2024-03-31 | $172.9M | −$88.1M | −33.75% | +9.15% |
| Q4 2023 | 2023-12-31 | $525.6M | $344.8M | +190.71% | +27.09% |
| Q3 2023 | 2023-09-30 | $253.3M | −$150.3M | −37.24% | +14.44% |
| Q2 2023 | 2023-06-30 | $250.6M | −$54.0M | −17.73% | +13.40% |
| Q1 2023 | 2023-03-31 | $261.0M | −$18.3M | −6.55% | +14.25% |
| Q4 2022 | 2022-12-31 | $180.8M | −$135.7M | −42.88% | +9.91% |
| Q3 2022 | 2022-09-30 | $403.6M | $14.5M | +3.73% | +24.17% |
| Q2 2022 | 2022-06-30 | $304.6M | −$124.7M | −29.05% | +17.10% |
| Q1 2022 | 2022-03-31 | $279.3M | $58.6M | +26.55% | +16.79% |
| Q4 2021 | 2021-12-31 | $316.5M | −$86.5M | −21.46% | +17.81% |
| Q3 2021 | 2021-09-30 | $389.1M | $38.4M | +10.95% | +23.09% |
| Q2 2021 | 2021-06-30 | $429.3M | $501.1M | — | +24.35% |
| Q1 2021 | 2021-03-31 | $220.7M | −$190.0M | −46.26% | +13.78% |
| Q4 2020 | 2020-12-31 | $403.0M | $31.5M | +8.48% | +33.91% |
| Q3 2020 | 2020-09-30 | $350.7M | −$168.6M | −32.47% | +18.18% |
| Q2 2020 | 2020-06-30 | −$71.8M | −$313.9M | — | −5.86% |
| Q1 2020 | 2020-03-31 | $410.7M | $164.9M | +67.09% | +23.02% |
| Q4 2019 | 2019-12-31 | $371.5M | $39.5M | +11.90% | +17.48% |
| Q3 2019 | 2019-09-30 | $519.3M | $96.7M | +22.88% | +27.44% |
| Q2 2019 | 2019-06-30 | $242.1M | −$124.2M | −33.91% | +12.17% |
| Q1 2019 | 2019-03-31 | $245.8M | −$218.0M | −47.00% | +12.44% |
| Q4 2018 | 2018-12-31 | $332.0M | −$24.7M | −6.92% | +16.03% |
| Q3 2018 | 2018-09-30 | $422.6M | −$4.9M | −1.15% | +23.01% |
| Q2 2018 | 2018-06-30 | $366.3M | −$43.5M | −10.61% | +18.25% |
| Q1 2018 | 2018-03-31 | $463.8M | $231.5M | +99.66% | +22.99% |
| Q4 2017 | 2017-12-31 | $356.7M | −$215.9M | −37.71% | — |
| Q3 2017 | 2017-09-30 | $427.5M | $131.3M | +44.33% | +23.58% |
| Q2 2017 | 2017-06-30 | $409.8M | $76.3M | +22.88% | — |
| Q1 2017 | 2017-03-31 | $232.3M | −$12.9M | −5.26% | — |
| Q4 2016 | 2016-12-31 | $572.6M | $159.2M | +38.51% | — |
| Q3 2016 | 2016-09-30 | $296.2M | $251.4M | +561.16% | — |
| Q2 2016 | 2016-06-30 | $333.5M | $166.7M | +99.94% | — |
| Q1 2016 | 2016-03-31 | $245.2M | $188.1M | +329.42% | — |
| Q4 2015 | 2015-12-31 | $413.4M | $100.7M | +32.20% | — |
| Q3 2015 | 2015-09-30 | $44.8M | −$178.6M | −79.95% | — |
| Q2 2015 | 2015-06-30 | $166.8M | −$55.3M | −24.90% | — |
| Q1 2015 | 2015-03-31 | $57.1M | −$100.3M | −63.72% | — |
| Q4 2014 | 2014-12-31 | $312.7M | $35.3M | +12.73% | — |
| Q3 2014 | 2014-09-30 | $223.4M | −$32.4M | −12.67% | — |
| Q2 2014 | 2014-06-30 | $222.1M | $54.8M | +32.76% | — |
| Q1 2014 | 2014-03-31 | $157.4M | −$5.2M | −3.20% | — |
| Q4 2013 | 2013-12-31 | $277.4M | −$47.3M | −14.57% | — |
| Q3 2013 | 2013-09-30 | $255.8M | −$62.1M | −19.53% | — |
| Q2 2013 | 2013-06-30 | $167.3M | −$39.4M | −19.06% | — |
| Q1 2013 | 2013-03-31 | $162.6M | −$25.3M | −13.46% | — |
| Q4 2012 | 2012-12-31 | $324.7M | −$22.4M | −6.45% | — |
| Q3 2012 | 2012-09-30 | $317.9M | $1.1M | +0.35% | — |
| Q2 2012 | 2012-06-30 | $206.7M | −$27.4M | −11.70% | — |
| Q1 2012 | 2012-03-31 | $187.9M | $22.8M | +13.81% | — |
| Q4 2011 | 2011-12-31 | $347.1M | $44.7M | +14.78% | — |
| Q3 2011 | 2011-09-30 | $316.8M | $10.4M | +3.39% | — |
| Q2 2011 | 2011-06-30 | $234.1M | −$23.5M | −9.12% | — |
| Q1 2011 | 2011-03-31 | $165.1M | −$82.8M | −33.40% | +14.80% |
| Q4 2010 | 2010-12-31 | $302.4M | −$54.8M | −15.34% | +26.65% |
| Q3 2010 | 2010-09-30 | $306.4M | −$23.8M | −7.21% | +31.75% |
| Q2 2010 | 2010-06-30 | $257.6M | $86.3M | +50.38% | +24.35% |
| Q1 2010 | 2010-03-31 | $247.9M | $94.2M | +61.29% | +23.33% |
| Q4 2009 | 2009-12-31 | $357.2M | $117.0M | +48.71% | +32.26% |
| Q3 2009 | 2009-09-30 | $330.2M | — | — | +33.85% |
| Q2 2009 | 2009-06-30 | $171.3M | — | — | +16.80% |
| Q1 2009 | 2009-03-31 | $153.7M | — | — | +15.48% |
| Q3 2008 | 2008-09-30 | $240.2M | — | — | +25.23% |
Zimmer Biomet Holdings free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from $1.09B to $1.47B, a compound annual growth rate of 6.15%. Zimmer Biomet Holdings's latest reported quarter, Q2 2026, generated $393.6M in free cash flow, an increase of 19.96% year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Zimmer Biomet Holdings filings at SEC.gov ↗